The following stocks are the leading risers and fallers on AIM on Thursday.
----------
AIM - WINNERS
----------
ImmuPharma PLC, up 90% at 2.28 pence, 12-month range 0.82p-3.00p. The drug discovery and development company hails ‘groundbreaking advancements’ in preclinical research in the autoimmune diseases space. ‘We are delighted to share these significant findings from ImmuPharma Biotech. This breakthrough research confirms our confidence in P140, its future therapeutic success and also creates potential new opportunities to strengthen our intellectual property portfolio, positioning us at the forefront of innovation in autoimmune disease therapies,’ Chief Executive Officer Tim McCarthy says. The firm is ‘not at this time releasing detailed data’ on the findings as they are part of an ongoing expansion of its intellectual property portfolio. However, it did say the findings pave the way for ‘earlier and more accurate diagnostics’ and make it easier to spot patients who are more likely to respond to the P140 treatment. The findings also suggest improved monitoring of treatment response.
----------
Cirata PLC, up 26% at 26.90p, 12-month range 19.05p-85.00p. The software solutions provider says it rounded off 2024 with the ‘strongest bookings quarter’ since the second-quarter of 2022. Bookings in the final-quarter of 2024 total $3.0 million, improving from $2.7 million a year prior and $1.7 million in the third-quarter. Annual bookings amount to $7.1 million for 2024, fading from $7.2 million for 2023.
----------
AIM - LOSERS
----------
Impax Asset Management Group PLC, down 3.4% at 234.34p, 12-month range 220.50p-559.00p. The firm reports assets under management decline 8.3% quarter-on-quarter to £34.11 billion at its December 31 first-quarter end. ‘This quarter we saw relatively high outflows, notably the closure of our smaller mandate with St James’s Place and redemptions driven by industry consolidation in our institutional channel in the Asia-Pacific region,’ CEO Ian Simm says. ‘More positively, we have continued to see a slow-down in outflows from our largest European distribution partner, BNP Paribas Asset Management, and from our US mutual funds.’ It reports net outflows of £2.42 billion for the period, as well as a £660 million hit from the performance, market movement, and foreign exchange.
----------
Copyright 2025 Alliance News Ltd. All Rights Reserved.
